

EmeritusDX Announces Launch of New Molecular Test, MetaDX™

NEWS PROVIDED BY

EmeritusDX

May 24, 2023, 13:20 ET

 EmeritusDX



The PCR-Based Test Aims to Personalize Treatment for Patients with Prostate Cancer

IRVINE, Calif., May 24, 2023 /PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the commercial availability of MetaDX™, a PCR-based assay designed to provide personalized treatment guidance for patients diagnosed with prostate cancer. Performed on biopsied prostate tissue, MetaDX™ measures the AR-V7/AR-WT Ratio to predict the patient's resistance to Androgen Deprivation Therapy (ADT) early on in the treatment process.

"MetaDX™ addresses an important treatment decision for patients diagnosed with prostate cancer," said Robert Embree, Chief Executive Officer, EmeritusDX. "By launching this test, we continue down our committed path of improving patient outcomes as well as reducing overall treatment costs."

"By launching this test, we continue down our committed path of improving patient outcomes as well as reducing overall treatment costs." Robert Embree, CEO



Advanced prostate cancer tends to be hormone sensitive and is often treated with androgen deprivation therapy. However, resistance to this therapy can develop through first, second, and third lines of therapy. "Our goal is to alert physicians when resistance to therapy is identified in these patients so that effective alternative treatments are provided in the earliest possible phase."

The MetaDX™ assay is currently available from EmeritusDX's Irvine, CA laboratory. The test is performed on paraffin embedded prostate tissue and is reported out within 3-5 days. Clients have the option of ordering this test as a reflex or on demand.

About EmeritusDX

EmeritusDX is a cancer diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.

If you would like more information about this topic, please call 800-959-2846 or email contact@emeritusdx.com

Media Contact

Chateau LaFite, KPA, EmeritusDX, 1 800.959.2846, contact@emeritusdx.com

SOURCE EmeritusDX